Premium
O4‐01‐08: Donepezil high‐dose extended‐release tablets provide greater benefit to moderate‐to‐severe Alzheimer patients already treated with donepezil immediate‐release tablets
Author(s) -
Farlow M.R.,
Salloway S.P.,
Tariot P.N.,
Yardley J.,
Moline M.,
Wang Q.,
Zou H.,
Brand-Schieber E.,
Satlin A.,
Hsu T.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.472
Subject(s) - donepezil , population , medicine , clinical endpoint , psychology , gastroenterology , cholinesterase , concomitant , alzheimer's disease , pharmacology , randomized controlled trial , disease , dementia , environmental health
outcome measure (CSF Ab42) at 9 months compared to placebo (n1⁄4 49) (p 1⁄4 0.895). However, APOE4 allele, baseline cholesterol levels, and baseline CSF biomarker levels interacted significantly with treatment to impact primary and secondary outcome measures. The results of these interactions will be presented. Conclusions: In middle-aged adults with parental history of AD, the effect of simvastatin on CSF, MRI perfusion, and cognitive AD biomarkers may be significantly influenced by underlying risk profile. Understanding how these factors influence response to therapy may help guide future trials assessing the role of statins in AD prevention.